insights_auto
Why is TGNA down 2,64%?
Dive Deeperchevron_right
TGNA:FRA
Transgene SA
€0,66
arrow_downward
-2,64%(-0,018) 1D
9 Okt., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€0,66
High
€0,66
Low
€0,66
Mkt. cap
186,60Â m
Avg. vol.
0,00
Volume
0,00
52-wk high
€1,48
52-wk low
€0,60
EPS
-€0,17
No. of employees
152
Open
€0,66
High
€0,66
Low
€0,66
Mkt. cap
186,60Â m
Avg. vol.
0,00
Volume
0,00
52-wk high
€1,48
52-wk low
€0,60
EPS
-€0,17
No. of employees
152
News stories
From web sources and news partners
Yahoo Finance
·
6 uur gelede
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
24/7 Wall St.
·
20 uur gelede
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
Seeking Alpha
·
14 uur gelede
The 1-Minute Market Report October 10, 2026 (NYSEARCA:VOO)
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA